On Thursday, June 28, 2012, at 2:30PM (ET), FDA will present a webinar to discuss the new draft guidance for industry entitled, “Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use of an Endpoint to Support Accelerated Approval”.
During this webinar, speakers from the Office of Hematology Oncology Products Breast Oncology Group will discuss the new draft guidance for industry entitled, “Pathologic Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use of an Endpoint to Support Accelerated Approval”.
For more information please visit Webinar.
http://links.govdelivery.com/track?type=click&enid=ZWFzPTEmbWFpbGluZ2lkPTIwMTIwNjIyLjg1MDA4NjEmbWVzc2FnZWlkPU1EQi1QUkQtQlVMLTIwMTIwNjIyLjg1MDA4NjEmZGF0YWJhc2VpZD0xMDAxJnNlcmlhbD0xNjkwMTYzMSZlbWFpbGlkPWppbXRha2VkYUBnbWFpbC5jb20mdXNlcmlkPWppbXRha2VkYUBnbWFpbC5jb20mZmw9JmV4dHJhPU11bHRpdmFyaWF0ZUlkPSYmJg==&&&100&&&http://1.usa.gov/BCWbnrL?source=govdelivery